Utama › Meningioma › Ohio
Kajian klinikal Meningioma di Ohio
7 kajian untuk Meningioma sedang mencari peserta di lokasi di Ohio.
Bandar di Ohio
Teks kajian rasmi (Bahasa Inggeris)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- dan 30 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT02523014A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- The Ohio State University College of Medicine (OSUCOM), Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07428616RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- Ohio State University Comprehensive Cancer Center, Columbus
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Ogo 2026 · NCT07150806Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Mayfield Brain and Spine, Cincinnati
- Kettering Health, Kettering
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 22 Jul 2026 · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
Mengambil pesertaFasa 1/2
Umur 4 hingga 39 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT05278208Cognitive Status After Removal of Skull Base Meningioma
- Ohio State University Wexner Medical Center, Columbus
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 89 · Semua jantina · Dikemas kini 22 Mei 2026 · NCT04635657Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- UH Cleveland Medical Center, Cleveland
- Ohio State University, Columbus
Mengambil pesertaFasa 1/2
Umur 18 hingga 90 · Semua jantina · Dikemas kini 14 Mei 2026 · NCT05636618Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.